Peptide Profile
Cetrorelix
Cetrotide · GnRH antagonist
Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH…
- Half-life
- ~62 hours
- Routes
- subcutaneous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Cetrorelix is
About Cetrorelix
Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression
Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval. Clinical studies including randomized controlled trials have established cetrorelix as an effective option for LH surge prevention in IVF and ICSI cycles, with well-characterized safety and efficacy data across multiple formulations. Cetrorelix is an FDA-approved prescription medication (Cetrotide) indicated for use under specialist supervision in fertility treatment settings. Cetrorelix dosing protocols and IVF context Per FDA labeling (Cetrotide), cetrorelix is available in two protocols for IVF: the multiple-dose protocol (0.25 mg subcutaneously once daily during ovarian stimulation) and the single-dose protocol (3 mg subcutaneously in a single injection). Specific timing, trigger criteria, and supplemental dosing schedules are determined by the treating reproductive endocrinologist per the full FDA prescribing information. Cetrorelix vs ganirelix: Cetrorelix (Cetrotide) and ganirelix (Antagon, Orgalutran) are both GnRH receptor antagonists used in the same IVF indication. Both act as competitive antagonists at the pituitary GnRH receptor, producing rapid suppression without the initial LH flare seen with agonists. They are pharmacologically equivalent in mechanism; differences relate to proprietary formulation, dosing schedule in specific protocols, and market availability in different regions. Neither requires the weeks-long downregulation period that GnRH agonist protocols (triptorelin, leuprolide) involve — antagonist protocols can begin mid-stimulation, reducing the total cycle length. Cetrorelix and ganirelix are both prescription-only fertility medications requiring specialist reproductive endocrinology supervision.
Women's Health
Cetrorelix (a GnRH antagonist) is FDA-approved to prevent premature LH surge during controlled ovarian stimulation in ART, supported by a large network meta-analysis. It is contraindicated in both pregnancy and lactation per its FDA label.
Cetrorelix Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Cetrorelix half-life
Why no half-life is shown
Cetrorelix’s half-life depends heavily on dose and formulation: roughly 5–10 hours after a single low-dose (0.25–1 mg) subcutaneous injection, rising to about 20–80 hours with the 3 mg depot or repeated dosing. Because a single number would mislead, the range is shown rather than one curve.
What the evidence says about Cetrorelix
Research Evidence
based on 7 studies · most recent 2026
Regulatory Status
- Availability Status
- Prescription
- FDA Status
- FDA Approved
FDA-approved GnRH antagonist. Brand: Cetrotide (NDA 021036, Jun 1999). Prevents premature LH surges in controlled ovarian stimulation. Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
7 sources cited · 2 strong · 3 moderate · 2 weak
2 Meta-analysis · 3 Cohorts · 2 Animals
GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
J Coll Physicians Surg Pak · 2026
# Summary Research found that in IVF/ICSI cycles for women with polycystic ovary syndrome, cetrorelix demonstrated the highest probability ranking for reducing ovarian hyperstimulation syndrome risk (96.9%), while leuprorelin ranked highest for improving clinical pregnancy and live birth rates. This network meta-analysis of 20 randomized controlled trials involving 2,400 patients suggested that treatment selection should be guided by individual patient priorities: cetrorelix for OHSS prevention and leuprorelin for pregnancy outcome optimization.
Optimal GnRH antagonist protocol for ovarian stimulation during ART: systematic review and network meta-analysis
Hum Reprod Update · 2023
Network meta-analysis (75 studies) supporting cetrorelix for premature LH-surge prevention in ART.
Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation syndrome: A cross-sectional study.
Int J Reprod Biomed · 2026
Show 4 more sources ↓
Effects of half-dose and full-dose GnRH antagonists on IVF-ET outcomes: a retrospective study
BMC Pregnancy and Childbirth · 2021
Research in 316 IVF-ET cycles found that half-dose cetrorelix (GnRH antagonist) yielded significantly more retrieved oocytes and available embryos than full-dose, with comparable pregnancy and live birth rates overall; among patients with BMI ≥25, half-dose was associated with higher clinical pregnancy rate, suggesting dose flexibility for patient-specific outcomes optimization.
Comparison of the effects of Duphaston and Cetrotide on oocyte and embryo quality in women undergoing ICSI: a cross-sectional study
International Journal of Reproductive Biomedicine · 2020
Research in a retrospective study of 200 ICSI patients found that cetrorelix (Cetrotide) effectively prevented premature LH surge during controlled ovarian hyperstimulation, with comparable follicle counts, oocyte maturation, and viable embryo numbers to oral dydrogesterone (Duphaston), providing comparative clinical evidence for GnRH antagonist protocols in assisted reproduction.
Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.
Eur J Pharm Sci · 2026
# Summary Research found that both oleogel and hydrogel formulations of cetrorelix acetate were successfully developed for nasal administration, with the hydrogel formulation demonstrating superior bioavailability (5.3%) and prolonged peptide absorption over 24 hours in animal studies. This study demonstrated that nasal gel delivery could represent a viable non-invasive alternative to invasive administration routes for this decapeptide therapeutic.
Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.
AAPS PharmSciTech · 2026
Cetrorelix Side Effects & Safety Considerations
Contraindications below are derived from the compound’s FDA label. Educational only — not medical advice.
Absolute contraindications
Situations where this compound should not be used. Educational only — not medical advice.
Source: FDA label
Common monitoring markers in research protocols
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSCetrorelix
Frequently Asked Questions — Cetrorelix
Cetrorelix is a synthetic GnRH antagonist peptide used in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surges during controlled ovarian stimulation protocols. By competitively blocking GnRH receptors in the pituitary gland, cetrorelix rapidly suppresses LH release without the initial hormonal flare seen with GnRH agonists, allowing more precise timing of oocyte retrieval.
HPG axis suppression, LH/FSH reduction, controlled ovarian stimulation support, testosterone management.
Research on Cetrorelix primarily documents effects related to HPG axis suppression and LH/FSH reduction and controlled ovarian stimulation support and testosterone management. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Cetrorelix include Pregnancy — contraindicated, Lactation — contraindicated. This is educational information only — consult a qualified healthcare professional before use.
For Cetrorelix, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
# Summary Research found that in IVF/ICSI cycles for women with polycystic ovary syndrome, cetrorelix demonstrated the highest probability ranking for reducing ovarian hyperstimulation syndrome risk (96.9%), while leuprorelin ranked highest for improving clinical pregnancy and live birth rates. This network meta-analysis of 20 randomized controlled trials involving 2,400 patients suggested that treatment selection should be guided by individual patient priorities: cetrorelix for OHSS prevention and leuprorelin for pregnancy outcome optimization.
How to get Cetrorelix
Where to buy Cetrorelix
Coverage expanding
No providers currently list Cetrorelix. Get notified when one does, or explore providers carrying similar peptides in the Sexual Health category.
Questions to ask your provider
Stay updated on Cetrorelix providers
New providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Reconstitution Calculator
Convert vial size + BAC water volume into draw volume.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.